Share Twitter LinkedIn Facebook Email Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of trastuzumab can be given rather than 12 months in the adjuvant setting
Strategizing Personalized Breast Cancer Treatment: A Promising Overview of Advances and Clinical Applications [39 SLIDES] Breast 4 Mins Read
Fertility Preservation: Interrupting endocrine therapy to attempt pregnancy in Breast Cancer Breast 2 Mins Read